• Human LILRB4/ILT-3/CD85k protein (Recombinant) (C-His) (STJP001196)
  • Human LILRB4/ILT-3/CD85k protein (Recombinant) (C-His) (STJP001196)
  • Human LILRB4/ILT-3/CD85k protein (Recombinant) (C-His) (STJP001196)
  • Human LILRB4/ILT-3/CD85k protein (Recombinant) (C-His) (STJP001196)
  • Human LILRB4/ILT-3/CD85k protein (Recombinant) (C-His) (STJP001196)
  • Human LILRB4/ILT-3/CD85k protein (Recombinant) (C-His) (STJP001196)

Human LILRB4/ILT-3/CD85k protein (Recombinant) (C-His) (STJP001196)

SKU:
STJP001196

Current Stock:
Host: HEK293 cells
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Recombinant-Human LILRB4/ILT-3/CD85k-C-His protein was developed from hek293 cells and has a target region of C-His. For use in research applications.
Formulation: Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. Contact us for customized product form or formulation.
Immunoreactivity: Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human LILRB4 at 5 Mu g/mL (100 Mu L/well) can bind Recombinant Human ANGPTL7 with a linear range of 0.12-0.5 Mu g/mL.2. Measured by its binding ability in a functional ELI
Gene Symbol: LILRB4
Gene ID: 11006
Uniprot ID: LIRB4_HUMAN
Immunogen: Recombinant Human LILRB4/ILT-3/CD85k Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Gln22-Glu259) of human LILRB4/CD85k/ILT3 (Accession #NP_001265356.2) fused with a 6Ă—His tag at the C-terminus.
Function Inhibitory receptor involved in the down-regulation of the immune response and the development of immune tolerance. Receptor for FN1. Receptor for apolipoprotein APOE. Receptor for ALCAM/CD166. Inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions. Inhibits FCGR1A/CD64-mediated monocyte activation by inducing phosphatase-mediated down-regulation of the phosphorylation of multiple proteins including LCK, SYK, LAT and ERK, leading to a reduction in TNF production. This inhibition of monocyte activation occurs at least in part via binding to FN1. Inhibits T cell proliferation, inducing anergy, suppressing the differentiation of IFNG-producing CD8+ cytoxic T cells and enhancing the generation of CD8+ T suppressor cells. Induces up-regulation of CD86 on dendritic cells. Interferes with TNFRSF5-signaling and NF-kappa-B up-regulation.
Protein Name Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 4
B4
Cd85 Antigen-Like Family Member K
Immunoglobulin-Like Transcript 3
Ilt-3
Leukocyte Immunoglobulin-Like Receptor 5
Lir-5
Monocyte Inhibitory Receptor Hm18
Cd Antigen Cd85k
Database Links Reactome: R-HSA-198933
Cellular Localisation Cell Membrane
Single-Pass Type I Membrane Protein
Ligand Binding Leads To Internalization And Translocation To An Antigen-Processing Compartment
Alternative Protein Names Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 4 protein
B4 protein
Cd85 Antigen-Like Family Member K protein
Immunoglobulin-Like Transcript 3 protein
Ilt-3 protein
Leukocyte Immunoglobulin-Like Receptor 5 protein
Lir-5 protein
Monocyte Inhibitory Receptor Hm18 protein
Cd Antigen Cd85k protein
LILRB4 protein
ILT3 protein
LIR5 protein

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance